Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in Metastatic Castration-Resistant Prostate Cancer
NCT02905318Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jul 2017
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in prostate cancer (PCa), sponsored by Canadian Cancer Trials Group. Primary endpoint: Clinical Benefit Rate at 36 months. Started Jul 2017; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02905318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905318.